Objectives: To assess whether individual blood glucose variability in critically ill children is associated with increased mortality and to define the temporal patterns of blood glucose variability during critical illness in children.
S tress hyperglycemia associated with insulin resistance is a common occurrence in critically ill adults and children. Contributing factors may include excessive administration of exogenous dextrose (rates, Ͼ5 mg/kg/min) as well as an increase in production of endogenous glucose, with the development of peripheral insulin resistance due to alterations in counterregulatory hormones, cytokines, and glucose transporters (1) (2) (3) (4) (5) . In the past, stress hyperglycemia was largely ignored or considered to represent an adaptive response to acute illness. Several studies (6 -18) in critically ill adults and children have highlighted a possible association between hyperglycemia and harm. Strict glycemic control with intensive insulin therapy has emerged as a rational therapy in selected critically ill adults to improve survival (19 -21) , but the benefits of such a strategy in critically ill children remain unknown, especially when weighed against the risks posed by hypoglycemia.
Recently, hypoglycemia and variability in blood glucose (BG) concentrations have also emerged as possible independent risk factors for harm in critically ill children (17, 22) . Wintergerst et al (17) demonstrated that both extremes of BG concentrations affect mortality and also observed that patients who had larger fluctuations in BG exhibited higher mortality. These larger fluctuations in BG may represent a failure of the body to maintain allostasis in the face of overwhelming stress, such as critical illness, and thus predispose the patient to harm (23) . However, it is unclear if BG variability in the individual patient exhibits a temporal pattern, according to the phase of illness. It is also unknown if strategies for BG control should take into account BG variability.
We therefore decided to assess whether individual BG variability in critically ill children is associated with increased mortality. We further sought to define the temporal patterns of BG variability in critical illness in children; we hypothesized that, whereas early alterations in BG variability may represent allostasis, later fluctuations in BG variability may be associated with reduced survival.
No topic is more important in pediatric critical care medicine than glucose control in critically ill children. Much has been written about hyperglycemia and intensive insulin therapy. An aspect of this topic that appears to be emerging is the potential importance of the timing of hyperglycemia and/or glucose variability. This report begins to address this very important issue for the pediatric intensivist. After completing this CME activity, physicians should be better able to assess serum glucose-related factors associated with mortality in critically ill children that may serve as targets for developing an optimal approach to glucose control in the pediatric intensive care unit (PICU), and they should be more apt to evaluate the concept that temporal factors may play an important role in the impact of glucose variability and its relationship to outcome.
MATERIALS AND METHODS
We performed a retrospective cohort review of patients admitted to the PICU of the Children's Hospital Los Angeles (a freestanding, tertiary care, academic children's hospital). Since January 2000, the PICU has employed a computerized database (Oracle platform) to track predefined patient-related characteristics and events of all PICU admissions. We retrospectively used this database to screen all patients for eligibility between January 2000 and December 2005. We included patients if they were between the ages of 0 -20 yrs and had at least 12 BG measurements taken within the first 72 hrs of PICU admission. We chose the latter inclusion criterion in order to have a sufficient number of glucose values with which to gain an adequate estimate of variability and we did not a priori control the frequency of BG measurements. We excluded patients if they had the diagnosis of diabetes mellitus or any metabolic disorder requiring insulin and dextrose infusions. We also excluded patients in the neonatal and cardiothoracic intensive care units in our institution. All patient data were obtained from the PICU database and included age, weight, gender, severity of illness scores (Pediatric Risk of Mortality), BG concentrations, insulin infusions, invasive mechanical ventilation, vasoactive infusions (vasopressors, inodilators, vasodilators), steroids, dextrose infusions, nutrition (parenteral infusions or enteral feeds), and PICU survival. During this time period, the PICU did not have a specific protocol to control BG concentrations. BG was measured by two different assay methods: central laboratory and intensive care unit laboratory. Samples included arterial, venous, and capillary blood sources. All BG measurements were included in the analysis. The range of BG values (BG range) was calculated for each patient, defined as the difference between maximum and minimum BG values (smallest from largest). We defined BG variability as the SD of BG concentrations in individual patients. BG variability was divided into tertiles from the least to the most variability. We also analyzed daily BG variability for each patient for the first week and beyond of PICU admission.
Statistical analysis was performed using Stata 8.0 software. The data are presented as the mean Ϯ SD or the median (interquartile range). Differences between survivors and nonsurvivors were compared using Student's t test (in the case of continuous variables that were normally distributed) or the MannWhitney U test (in the case of continuous variables that were not normally distributed). Differences in categorical variables were compared using the chi-square test or Fisher's exact test. Multiple group comparisons were performed between the BG tertiles, using either analysis of variance (or the nonparametric equivalent) or chi-square with Bonferroni's correction. After determination of individual factors associated with PICU mortality by univariate analysis, a multiple logistic regression model of important factors associated with PICU mortality was developed. The results of the regression were presented as adjusted odds ratios with 95% confidence intervals.
This study was approved by the Institutional Review Board at Children's Hospital Los Angeles.
RESULTS
A total of 4,911 patients were screened and 101 patients were eligible for our study. These 101 patients had 3,144 measured BG concentrations with a mean BG of 141.6 Ϯ 86.4 mg/dL (7.9 Ϯ 4.8 mmol/L) and a median BG of 120 mg/dL (6.7 mmol/L). Of the study patients, 26% (27 of 101 patients) received steroids and 25% (25 of 101 patients) received insulin infusions. Table 1 lists patient demographics.
Nonsurvivors had higher median BG concentrations than survivors (129 mg/dL vs. 118 mg/dL, p Ͻ .01) ( Table 2 ). All patients had BG of Ͼ110 mg/dL. Nonsurvivors had greater prevalence both of hyperglycemia with BG of Ͼ180 mg/dL (100% vs. 73%, p Ͻ .05) and BG of Ͼ200 mg/dL (88% vs. 59%, p Ͻ .05) and of hypoglycemia (BG of Ͻ60 mg/dL) (56% vs. 15%, p Ͻ .01) compared with survivors. Few patients had BG of Ͻ40 mg/dL. The mean BG range was greater in nonsurvivors compared with survivors (257 mg/dL vs. 185 mg/dL, p Ͻ .01) as was the BG variability (63 mg/dL vs. 45 mg/dL, p ϭ .02). BG variability tertiles were proportionately associated with increasing mortality: 6% vs. 15% vs. 27% (p ϭ .07). Patients in the third tertile with the greatest BG variability had higher Pediatric Risk of Mortality scores and received more insulin infusions (Table 3 ). The BG variability of those patients who received insulin was significantly higher during the first 72 hrs (57 mg/dL vs. 41 mg/dL, p Ͻ .05) as well as after 72 hrs (60 mg/dL vs. 28 mg/dL, p Ͻ .05). The glucose infusion rates did not differ between the insulin and noninsulin groups (3.8 mg/ kg/min vs. 3.3 mg/kg/min, p ϭ .41), and the insulin group had a higher mortality (32% vs. 11%, p ϭ .01).
Daily BG variability is represented in Figure 1 . On day 1 (0 -24 hrs), both survivors and nonsurvivors exhibited the most BG variability of any single day in the PICU. The BG variability was significantly greater in nonsurvivors than in survivors (57 mg/dL vs. 42 mg/dL, p Ͻ .05). Over the subsequent days, BG variability substantially decreased in both groups, with a greater reduction in survivors. After day 4, BG variability increased more in nonsurvivors than in survivors, with the daily differences becoming significant after day 8 (59 mg/dL vs. 40 mg/dL, p Ͻ .05).
During the first 72 hrs of PICU admission, neither the mean BG nor the BG variability were significantly different between nonsurvivors and survivors (mean BG, 159 mg/dL vs. 135 mg/dL, p ϭ .53; BG variability, 59 mg/dL vs. 43 mg/dL, p ϭ .12). After the first 72 hrs of PICU admission until discharge, both the mean BG and the BG variability were significantly higher in nonsurvivors compared with survivors (mean BG, 157 mg/dL vs. 127 mg/dL, p ϭ .02; BG variability, 52 mg/dL vs. 33 mg/dL, p Ͻ .05). After controlling for potential confounders associated with PICU mortality, individual BG variability was associated with higher PICU mortality for each mg/dL increase in BG variability (adjusted odds ratio, 1.03; 95% confidence intervals, 1.01-1.05) ( Table 4) . 
DISCUSSION
Stress hyperglycemia and insulin resistance are commonly seen in critically ill patients. Earlier studies (10, (15) (16) (17) have demonstrated the association of hyperglycemia with worse outcomes in critically ill children. Srinivasan et al (15) observed associations of peak BG and duration of hyperglycemia with mortality in critically ill children requiring mechanical ventilation and/or vasoactive infusions. More recently, Wintergerst et al (17) reported associations of not only hyperglycemia but also hypoglycemia and BG variability with mortality in a cohort of PICU patients. Our study findings concur with the results of these earlier studies. Additionally, our study emphasizes that fluctuations in BG are extensive in critically ill children and seem to exhibit a dose-response effect with mortality. Fluctuations in BG may serve as a better discriminator of outcomes than either hyperglycemia or hypoglycemia alone, especially in the later phases of critical illness. We speculate that whereas BG fluctuations in the early phases of illness may represent allostasis and physiologic adaptation, BG variability in the later phases of illness may signify failure of compensatory mechanisms.
Why might BG variability be an important risk factor for poor outcomes from critical illness? During health, BG concentrations are maintained within a "normal range" largely due to mechanisms involving feedback loops and insulin signaling pathways. These mechanisms involve a combination of homeostasis (physiologic resistance to change) and allostasis (physiologic adaptation to change). Critical illness is characterized by stressors, such as inflammation or injury, which provoke a stress response. From a teleological perspective, the stress response is a programmed, coordinated, and adaptive process to confer a survival advantage during acute illness (23) . With advances in medicine, more children survive the acute phase and progress to a phase of chronic critical illness. In these circumstances, persistence of the stress response might be maladaptive and result in secondary damage (23) . BG fluctuations in the acute phase of illness may therefore represent allostasis and even be helpful in ensuring survival of the organism, whereas continued BG fluctuations during the chronic phase of illness may represent secondary damage and thus contribute to poor outcomes.
In the first 24 hrs after admission to the PICU, nonsurvivors exhibited marked BG variability, the most we had seen out of any single day in the PICU. As survivors also exhibited considerable BG variability, it is likely that BG variability in the early phases of illness up to 72 hrs represents a vigorous stress response. Over the next few days, the BG variability becomes substantially less, illustrating the allostasis or "simmering down" of the stress response as it relates to changes in BG. After 1 wk, we demonstrated that there are patients with persistent BG variability, significantly greater in nonsurvivors compared with survivors. These patients likely have an inability to maintain BG allostasis and potentially represent a population that may respond to targeted BG control.
The findings from our study may represent a failure of autoregulation during chronic illness and may have important implications for the timing of application of glycemic control protocols during critical illness in children. Since the work of van den Berghe et al (19) in 2001, strict glucose control with intensive insulin therapy in critically ill adults has led to a care standard where glucose control with insulin protocols has been widely adopted (18) , a standard endorsed by several academic societies and organizations (24 -26) . In this study, children treated with insulin had among the greatest variability noted in the cohort and exhibited an increased mortality compared with children not treated with insulin. At the time of this study, no insulin protocol was in place; rather, the decision to initiate insulin treatment was at the discretion of the attending physician caring for the patient. Some of the patients with the greatest fluctuations in BG were treated with insulin, but given the lack of protocols and standardized therapies, the mortality likely reflects the magnitude of the variability, rather than the treatment with insulin.
Recently, controversies have emerged relating to the temporal application of insulin protocols, the observation of increased hypoglycemic events, and decreased benefits (20, 27) . Although many PICUs have adopted glucose control protocols with intensive insulin therapy, to date there have been no data in children regarding whether it improves survival or outcomes from critical illness. The occurrence of hypoglycemia as a result of intensive insulin therapy is one of the biggest concerns in the PICU. Studies from the previous decade (22, 28) have demonstrated that insulin-induced hypoglycemia may be detrimental to the developing pediatric brain. Studies conducted more recently (11) (12) (13) (14) have demonstrated that both hyperglycemia and hypoglycemia are independent risk factors for mortality in critically ill children. In this context, glucose control protocols may need to minimize BG variability and maintain BG concentrations within a "narrow" normal range. Additionally, the timing of institution of such practices may need to take into account the phase of critical illness. Premature control of BG concentrations in the early phases of critical illness may interfere with the "natural" stress response and prove to be harmful. Protocols employing strict BG control and intensive insulin therapy may have greater efficacy and improvement in outcomes if instituted after the acute phase of critical illness subsides.
There are several limitations to our study. It was a retrospective review of a limited cohort that was selected based on having Ͼ12 BG values within the first 72 hrs of PICU admission. This cohort may not have been representative of the entire PICU population due to selection bias. We examined daily BG variability between survivors and nonsurvivors but were limited by small sample size with dropouts over time due to death or PICU discharge. Studies with larger sample sizes are necessary to definitively test our hypothesis in the acute and chronic phases of critical illness and to further elucidate the timing. Further limitations include the variety of BG assay methods used to measure the BG concentrations, in addition to the varying sources of blood (arterial, venous, or capillary). Additionally, there were varying frequencies of blood sampling that could not be controlled. It is possible that had the BG concentrations been checked more frequently, we would have found the BG variability to have been even wider than that observed.
CONCLUSIONS
We observed that BG variability in critically ill children is common and associated with increased mortality in a dose-response fashion. We demonstrated the well-documented associations of hyperglycemia and hypoglycemia with mortality in this population. Furthermore, we attempted to characterize the temporal patterns of BG variability during critical illness in children. Whereas early alterations in BG variability during acute illness may represent allostasis and physiologic adaptation, later fluctuations in BG variability during chronic illness may represent maladaptation and, in turn, may be associated with reduced survival.
Close monitoring and control of BG variability may need to be incorporated into glycemic control regimens in critically ill children. Furthermore, the natural history of BG variability during critical illness suggests that control of BG after the acute phase of critical illness may be the logical approach to improve outcomes for critical illness. Ultimately, we need a large randomized pediatric trial of strict glucose control with intensive insulin therapy to answer these important questions. This report adds to the body of data supporting the concept that blood glucose variability is common in the PICU and is associated with mortality. Delayed occurrence of glucose variability may represent a particularly high-risk event in critically ill children with emerging problems in the subacute or chronic phase of their illness. After completing this CME activity, physicians should be better able to assess serum glucose-related factors associated with mortality in critically ill children that may serve as targets for developing an optimal approach to glucose control in the PICU, and they should be more apt to evaluate the concept that temporal factors may play an important role in the impact of glucose variability and its relationship to outcome.
